期刊
FRONTIERS IN MICROBIOLOGY
卷 11, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fmicb.2020.01105
关键词
Remdesivir (GS-5734); antivirals; EV71; vRNA; cRNA; enterovirus
类别
资金
- National Key Research and Development Program of China [2016YFC1200400]
- National Natural Science Foundation of China [81871697, 31600131, 81702003]
- Open Fund of the State Key Laboratory of Pathogenic Microbial Biosafety [SKLPBS1834]
- Key Research and Development Program of Shaanxi Province [2020SF-227, 2018JSTS03]
Human enteroviruses are responsible for diverse diseases, from mild respiratory symptoms to fatal neurological complications. Currently, no registered antivirals have been approved for clinical therapy. Thus, a therapeutic agent for the enterovirus-related disease is urgently needed. Remdesivir (GS-5734) is a novel monophosphoramidate adenosine analog prodrug that exhibits potent antiviral activity against diverse RNA virus families, including positive-senseCoronaviridaeandFlaviviridaeand negative-senseFiloviridae,Paramyxoviridae, andPneumoviridae. Currently, remdesivir is under phase 3 clinical development for disease COVID-19 treatment. Here, we found that remdesivir impeded both EV71 viral RNA (vRNA) and complementary (cRNA) synthesis, indicating that EV71 replication is inhibited by the triphosphate (TP) form of remdesivir. Moreover, remdesivir showed potent antiviral activity against diverse enteroviruses. These data extend the remdesivir antiviral activity to enteroviruses and indicate that remdesivir is a promising antiviral treatment for EV71 and other enterovirus infections.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据